Inhalation Sciences Sweden ABNGM: ISAB

ISAB: Sharp revenue drop and ongoing losses; financing and going concern remain key risks

· Issued by Inhalation Sciences Sweden AB

Revenue declined sharply in 2025, with a significant operating loss and ongoing negative cash flow. The order backlog improved, but future financing remains uncertain, and a strategic review for potential sale is underway. Material uncertainty exists regarding going concern.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Inhalation Sciences Sweden AB on 6ix

Earlier from Inhalation Sciences Sweden

Later from Inhalation Sciences Sweden

All Inhalation Sciences Sweden news releases